PharmAla Completes GMP Manufacture of ALA-002 Drug Substance

Jupiter Neurosciences has signed a definitive licensing agreement with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented formulation of MDMA, in a deal valued at up to $100 million including milestones. The transaction transforms Jupiter into a dual clinical-stage CNS company, adding ALA-002 to its existing Phase II Parkinson's disease program for JOTROL, a proprietary enhanced bioavailability resveratrol formulation. Chairman and CEO Christer Rosén and President Alison Silva discussed the acquisition during a fireside chat hosted by IPO Edge, noting the primary indication for ALA-002, its addressable market size, and potential revenue relative to the acquisition cost. They also addressed the status of the Phase II Parkinson's trial, the evolving U.S. regulatory landscape for psychedelics, and key milestones across the company's portfolio.

Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.